Autolus Therapeutics PLC (NAS:AUTL)
$ 3.92 0.05 (1.29%) Market Cap: 1.04 Bil Enterprise Value: 335.67 Mil PE Ratio: 0 PB Ratio: 1.79 GF Score: 55/100

Autolus Therapeutics PLC at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 01:20PM GMT
Release Date Price: $14.32 (+1.63%)
Unidentified Analyst

Good morning, everybody. Thanks for joining us for the next session. Pleased to have Autolus with us. Quickly before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up a copy at the registration desk.

So Christian, pleased to have you with us. Christian is the CEO of Autolus.

Questions & Answers

Unidentified Analyst

And I thought maybe just to start us off, there's lots of cell therapy companies out there, there's a lot of investment in cell therapy. Maybe you could just broadly talk about what you think differentiates Autolus in your approach versus some of the other cell therapy companies out there?

Christian Martin Itin
Autolus Therapeutics plc - Chairman & CEO

Well, first of all, thanks for having us at the conference, a real pleasure. You're absolutely

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot